Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-9: idecabtagene vicleucel plus lenalidomide maintenance versus lenalidomide maintenance alone after ASCT in newly diagnosed multiple myeloma
MOH_2023-08-15_012882Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2023
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Abecma plus Revlimid maintenance with Revlimid maintenance alone (2 arms). Started Aug 2023; status: active, not recruiting.
02
Drugs
idecabtagene vicleucellenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-08-15_012882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-15_012882.